Adding Tafasitamab Cuts Risk of Disease Progression, Relapse, or Death in Patients with Recurrent or Refractory Follicular Lymphoma [Yahoo! Finance]
Incyte Corporation (INCY)
Last incyte corporation earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
incyte.com/ir/investor-overview.aspx
Company Research
Source: Yahoo! Finance
LBA-1 : Tafasitamab Plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: Results from a Phase III Study (inMIND) SAN DIEGO Dec. 10, 2024 /PRNewswire/ -- Patients with follicular lymphoma that did not respond to or recurred after prior therapy experienced a 57% reduction in the risk of disease progression, relapse, or death when treated with tafasitamab in addition to two standard drugs compared with patients who received a placebo plus these two drugs. This is according to findings presented during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition. "Addition of the novel immunotherapy agent tafasitamab to a standard regimen that paired another immunotherapy agent, rituximab, with lenalidomide resulted in clinically meaningful improvement in the number of patients benefiting from treatment and in the duration of benefit," said principal investigator Laurie H. Sehn , MD, MPH , a clinical professor with the BC Cancer Centre for Ly
Show less
Read more
Impact Snapshot
Event Time:
INCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INCY alerts
High impacting Incyte Corporation news events
Weekly update
A roundup of the hottest topics
INCY
News
- Incyte Co. (NASDAQ: INCY) had its price target raised by analysts at Wells Fargo & Company from $68.00 to $70.00. They now have an "equal weight" rating on the stock.MarketBeat
- Incyte Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- INCYAccesswire
- Levi & Korsinsky Reminds Incyte Corporation Investors of the Ongoing Investigation into Potential Violations of Securities Laws - INCYAccesswire
- Incyte Co. (NASDAQ: INCY) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $77.00 price target on the stock.MarketBeat
- Incyte to Present at Upcoming Investor ConferenceBusiness Wire
INCY
Earnings
- 10/29/24 - Beat
INCY
Sec Filings
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- 1/3/25 - Form 4
- INCY's page on the SEC website